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The neurobehavioral consequences of fetal or
childhood pesticide exposure are a major bio-
medical and societal concern (Eriksson 1997;
Eriksson and Talts 2000; Landrigan 2001;
Landrigan et al. 1999; May 2000; Physicians
for Social Responsibility 1995). Chlorpyrifos
(CPF), one of the most widely used
organophosphate pesticides, is a developmen-
tal neurotoxicant specifically targeting the
immature brain (Barone et al. 2000; Pope
1999; Rice and Barone 2000; Slotkin 1999).
Recent U.S. regulatory provisions have thus
curtailed the domestic use of CPF (U.S.
Environmental Protection Agency 2000),
although worldwide use, particularly in agri-
culture, will continue for the foreseeable
future. The actual mechanisms by which CPF
perturbs neural development remain elusive
and complicated. A variety of in vitro and in
vivo model systems indicate impairment of
neural cell replication and differentiation, as
well as disruption of axonogenesis and synap-
tic function, all culminating in disruption of
behavioral performance (for reviews, see
Barone et al. 2000; Pope 1999; Slotkin
1999). Superimposed on neurospecific
effects, CPF may exert more generalized cyto-
toxicity from oxidative stress that affects the
developing brain because of its lower reserve
of antioxidants (Bagchi et al. 1995, 1996;
Crumpton et al. 2000).
One unusual property of CPF is the
apparently wide window of maturational vul-
nerability, with adverse neurodevelopmental
effects noted for exposures ranging from
embryonic stages through the postweaning
period (Barone et al. 2000; Buznikov et al.
2001; Dam et al. 2000; Garcia et al. 2001,
2002; Levin et al. 2001; Pope 1999; Qiao et
al. 2002; Rice and Barone 2000; Roy et al.
1998; Slotkin 1999; Slotkin et al. 2001,
2002). Recent findings from our laboratory
(Garcia et al. 2001, 2002; Qiao et al. 2001)
and others (Barone et al. 2000; Monnet-
Tschudi et al. 2000) suggest that CPF has a
shifting cellular target, initially impairing
development of neurons and subsequently
affecting glia, which develop much later
(Aschner 2000; Garcia et al. 2001, 2002;
Monnet-Tschudi et al. 2000; Qiao et al.
2001). All three major classes of glia, astro-
cytes, oligodendrocytes, and microglia, are
critical to brain development (Aschner et al.
1999; Barone et al. 2000; Compston et al.
1997; Guerri and Renau-Piqueras 1997).
Astrocytes provide nutrition, structural sup-
port, and protection from oxidative stress,
and additionally guide migrating neurons;
oligodendrocytes ensheath axons with myelin;
and microglia serve as macrophages (Aschner
et al. 1999; Barone et al. 2000; Compston et
al. 1997; Guerri and Renau-Piqueras 1997).
In most brain regions, neurons exit the cell
cycle and undergo terminal differentiation
relatively early (i.e., prenatally in the rat),
whereas gliogenesis and glial cell differentia-
tion continue well into postnatal develop-
ment (Aschner et al. 1999; Barone et al.
2000; Cameron and Rakic 1991; Compston
et al. 1997; Guerri and Renau-Piqueras 1997;
Wiggins 1986). The cerebellum, the brain
region that develops last, is an exception, with
a peak of neurogenesis in the second postna-
tal week (Rodier 1988). The finding that
CPF targets glia as well as (or perhaps more
than) neurons (Barone et al. 2000; Garcia et
al. 2001, 2002; Monnet-Tschudi et al. 2000;
Qiao et al. 2001) thus provides a partial
explanation for the exceptionally long matu-
rational period in which brain development is
sensitive to this agent. Interference with the
numerous roles of glia in synapse formation
(Ullian et al. 2001), axon migration, and
myelination (Compston et al. 1997; Riederer
et al. 1992) may all contribute to eventual
adverse outcomes.
In a recent study (Garcia et al. 2002), we
evaluated the effects of CPF exposure on glial
ﬁbrillary acidic protein (GFAP), an astrocyte-
associated protein (Garcia et al. 2002). In
keeping with the concept that CPF targets
glial development, postnatal treatment ini-
tially decreased GFAP levels. However, sev-
eral weeks later we found elevations of GFAP,
a pattern typically associated with gliosis in
response to injury to other neural cells
(Norton et al. 1992; O’Callaghan 1993).
This implied that astroglia were not the only
target for CPF. Furthermore, with prenatal
CPF treatment, unless the dose was raised
above the threshold for systemic toxicity, we
did not find any changes in GFAP, despite
the fact that fetal CPF exposure evokes
changes in brain morphology (Lassiter et al.
2002; White et al. 2002) and subsequent
behavioral anomalies (Levin et al. 2002).
Accordingly, in the current study we exam-
ined the potential for CPF to perturb the
development of other neural cell populations,
using a design similar to our GFAP study
(Garcia et al. 2002). We compared the effects
of prenatal versus postnatal CPF exposure on
the development and regional targeting of
myelin basic protein (MBP) and the small
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The developmental neurotoxicity of the organophosphate pesticide chlorpyrifos (CPF) is thought
to involve both neurons and glia, thus producing a prolonged window of vulnerability. To charac-
terize the cell types and brain regions involved in these effects, we administered CPF to developing
rats and examined neuroprotein markers for oligodendrocytes (myelin basic protein, MBP), for
neuronal cell bodies (neuroﬁlament 68 kDa, NF68), and for developing axons (neuroﬁlament 200
kDa, NF200). Prenatal CPF administration on gestational days (GDs) 17–20 elicited an immedi-
ate (GD21) enhancement of MBP and NF68; by postnatal day (PN) 30, however, there were
deﬁcits in all three biomarkers, with the effect restricted to females. Exposure in the early postna-
tal  period,  PN1–4, did not evoke signiﬁcant short-term or long-term changes in the neuropro-
teins. However, with treatment on PN11–14, we found reductions in MBP in the immediate
posttreatment period (PN15, PN20) throughout the brain, and deﬁciencies across all three pro-
teins emerged by PN30. With this regimen, males were targeted preferentially. The sex-selective
effects seen here for the GD17–20 and PN11–14 regimens match those reported earlier for subse-
quent behavioral performance. These results indicate a shift in the populations of neural cells tar-
geted by CPF, dependent upon the period of exposure. Similarly, developmental differences in the
sex selectivity of the biochemical mechanisms underlying neurotoxicant actions are likely to con-
tribute to discrete behavioral outcomes. Key words: brain development, chlorpyrifos, glia, myelin
basic protein, neurofilament protein, oligodendrocytes. Environ Health Perspect 111:297–303
(2003). doi:10.1289/ehp.5791 available via http://dx.doi.org/ [Online 30 October 2002]
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proteins (NF68 and NF200). MBP, an oligo-
dendrocyte marker, is a major component of
myelin and increases with oligodendrocyte
differentiation and myelination, primarily
during the second and third postnatal weeks
in the rat (Wiggins 1986). The neuroﬁlament
proteins are found in neurons and assemble
to form intermediate filaments that regulate
axon growth, axoplasmic transport, and axon
caliber (Capano et al. 2001; Escurat et al.
1990; Lee and Cleveland 1996; Schlaepfer
and Bruce 1990). NF68 is expressed early in
the postmitotic development of neuronal cell
bodies, whereas NF200 expression is associ-
ated primarily with the later growth of axons
(Capano et al. 2001; Carden et al. 1987;
Escurat et al. 1990; Lee and Cleveland 1996;
Schlaepfer and Bruce 1990; Yang et al.
1996). By examining these neuroprotein
markers, we can now elucidate how the cellu-
lar target and regional specificity for CPF-
induced alterations of brain development
shift with development.
Materials and Methods
Animal treatments. All experiments were con-
ducted in accordance with the Declaration of
Helsinki and with the Guide for the Care and
Use of Laboratory Animals as adopted and pro-
mulgated by the National Institutes of Health.
Timed-pregnant Sprague-Dawley rats (Zivic
Laboratories, Pittsburgh, PA) were housed in
breeding cages, with a 12-hr light-dark cycle
and free access to food and water. CPF (Chem
Service Inc., West Chester, PA) was dissolved
in dimethylsulfoxide to provide rapid and
complete absorption (Whitney et al. 1995)
and was injected subcutaneously in a volume
of 1 mL/kg body weight. For prenatal CPF
exposure, dams were injected daily with CPF
in doses of 1–40 mg/kg of body weight, or
with vehicle. Twenty-four hours after the last
injection [gestational day (GD) 21], fetuses
were removed and brains were dissected.
Additional dams in the control, 1 mg/kg, and
5 mg/kg treatment groups were allowed to
reach term, at which point their pups were
randomized within treatment groups and
redistributed to the nursing dams with a litter
size of 10 to maintain a standard nutritional
status. Randomization was repeated at inter-
vals of several days; in addition, dams were
rotated among litters to distribute any mater-
nal caretaking differences randomly across lit-
ters and treatment groups. Animals were
weaned on PN21, and all determinations
used no more than one male and one female
from each litter. 
For measurements on GD21, fetal brains
were separated into forebrain and the rest of the
brain by making a cut rostral to the thalamus.
Because the cerebellum represents an inappre-
ciable proportion of brain weight on GD21,
the remainder was designated “midbrain +
brainstem.” For studies on PN5, PN10,
PN15, and PN21, brains were dissected
into three regions: blunt cuts were made
through the cerebellar peduncles, where-
upon the cerebellum (including flocculi)
was lifted from the underlying tissue. Then,
as for the fetal brain, a cut was made rostral
to the thalamus to separate the forebrain
from the midbrain + brainstem. This dissec-
tion, which follows the planes of the fetal
and neonatal rat brain, includes the corpus
striatum, hippocampal formation, and neo-
cortex within the area designated “fore-
brain.” The region designated “midbrain +
brainstem” includes the midbrain, colliculi,
pons, and medulla oblongata (but not cervi-
cal spinal cord), as well as the thalamus. On
PN30, brains were dissected into the same
three major regions, and the midbrain +
brainstem and forebrain were further subdi-
vided into midbrain, brainstem, cerebral
cortex, hippocampus, and striatum.
For postnatal CPF treatments, all pups
were randomized the day after birth and
redistributed to the dams as already
described. For studies of CPF effects in the
ﬁrst few days after birth, animals were given 1
mg/kg daily on PN1–4. For studies in older
animals, which tolerate higher doses
(Campbell et al. 1997; Pope and Chakraborti
1992; Pope et al. 1991; Whitney et al. 1995),
daily treatment with 5 mg/kg was given on
PN11–14. These doses have been shown pre-
viously to alter neural function without elicit-
ing overt systemic toxicity (Campbell et al.
1997; Song et al. 1997; Whitney et al. 1995).
Behavioral differences remain apparent, or
may first emerge, after weaning, despite the
rapid recovery of cholinesterase activity
(Dam et al. 2000; Song et al. 1997). Neither
regimen evokes weight loss or mortality
(Campbell et al. 1997; Dam et al. 1998;
Johnson et al. 1998; Song et al. 1997), and
in the current study we did not observe any
changes in suckling or maternal caretaking.
Animals were weaned and selected from each
litter as detailed above.
Tissues were frozen in liquid nitrogen and
stored at –45°C.
Assays. Neurospecific proteins were
assayed by a modified (Garcia et al. 2002)
dot-immunobinding technique (O’Callaghan
1991; O’Callaghan et al. 1999). Briefly, tis-
sues were homogenized with a sonic probe
(Heat Systems-Ultrasonics, Inc., Plainview,
NY) in nine volumes of hot 1% sodium dode-
cyl sulfate (Bio-Rad, Hercules, CA) and were
diluted in 120 mM KCl, 20 mM NaCl, 2
mM MgCl2, 2 mM NaHCO3, 0.7% Triton
X-100, 0.2% NaN3, and 5 mM HEPES (pH
7.4). Ten-microliter aliquots containing
2–15 µg protein were blotted onto prewashed
nitrocellulose membranes (0.2 µm; Bio-Rad).
Blots were dried and fixed in 25% iso-
propanol, 10% acetic acid, and 65% water,
incubated for 5 min in Tris-buffered saline
(200 mM NaCl, 50 mM Tris, 0.002% NaN3,
pH 7.4) and treated for 1 hr with a blocking
solution of 0.5% gelatin (EIA grade; Bio-Rad)
in Tris-buffered saline. Blots were then incu-
bated in blocking solution containing 0.1%
Triton X-100 with addition of the appropriate
antibodies (Chemicon International Inc,
Temecula, CA): rabbit polyclonal anti-NF68
(diluted 1:2,000), rabbit polyclonal anti-
NF200 (diluted 1:2,000), or mouse mono-
clonal anti-MBP (diluted 1:300). Because the
MBP antibody was monoclonal, blots also
were incubated with rabbit anti-mouse IgG
(1:500; Dako Corporation, Carpentaria, CA)
in blocking solution with Triton. To assess
antibody binding, blots were incubated with
20 µCi [125I]Protein-A (speciﬁc activity, 382
Ci/mmol; Perkin-Elmer Life Sciences, Boston,
MA) in blocking solution with Triton X-100,
washed repeatedly, dried overnight, and
counted for radioactivity.
Each blot included serial dilutions of a
single preparation of adult midbrain, which
was then used to construct a standard curve
to normalize the values across blots. Thus,
although values are reported in relative units,
quantitative comparisons across treatments,
regions, and ages could be carried out.
Because the development of NF200 is
delayed relative to MBP and NF68 (Capano
et al. 2001; Escurat et al. 1990; Lee and
Cleveland 1996; Schlaepfer and Bruce 1990),
determinations for this neurospeciﬁc protein
were limited to PN30.
Study design and data analysis.
Experiments were conducted on four differ-
ent cohorts of animals. Two cohorts were
used for CPF exposure on GD17–20, with
each cohort comprising at least 12 dams per
treatment group. One cohort received 0, 1, 2,
or 5 mg/kg daily, whereas the second received
0, 10, 20, or 40 mg/kg per day. The other
two cohorts, again with at least 12 litters per
treatment group, were used for CPF expo-
sures on PN1–4 and PN11–14. For presenta-
tion purposes, control values were combined
across cohorts, as they did not differ signifi-
cantly from each other. However, treatment
differences were established using only the
control values for each matched cohort.
Data were compiled as means and stan-
dard errors. Differences between treatment
groups were assessed first by a multivariate
ANOVA (data log-transformed because of
heterogeneous variance) incorporating all rel-
evant variables: treatment (control, CPF),
treatment period (regimen), age, region, sex,
and neuroprotein (MBP, NF68, NF200).
Whenever the initial ANOVA indicated an
interaction of CPF treatment with other vari-
ables, data were separated according to the
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ANOVAs were conducted. Individual differ-
ences between control and CPF groups were
then evaluated post hoc by Fisher’s protected
least significant difference. However, in the
absence of interaction terms, only main treat-
ment effects were compiled, without subdivi-
sion into individual determinations. For
convenience, some data are presented as the
percentage change from the corresponding
controls, but statistical signiﬁcance was always
assessed on the original data. Control data
were combined across the different treatment
regimens (GD17–20, PN1–4, PN11–14) for
presentation purposes, but in all cases, CPF
effects were established using only the
matched control groups. For experiments
involving dose–effect determinations, data
were analyzed by multiple regression, incor-
porating all variables (dose, brain region, neu-
roprotein). Significance was assumed at the
level of p < 0.05 for main effects; for interac-
tions at p < 0.1, we examined lower-order
main effects after subdivision of the interac-
tive variables (Snedecor and Cochran 1967).
Results
Development of neuroproteins in controls.
Both MBP and NF68 were measurable at all
ages from GD21 through PN30, whereas
accurate determinations of NF200 were lim-
ited to PN30. In control brain, MBP (Figure
1A) was low in the fetus, without signiﬁcant
distinctions between the midbrain + brain-
stem and the forebrain. Regional differences
emerged postnatally, with the greatest
increases evident in postnatal weeks 2–4, in
agreement with earlier findings (Wiggins
1986). By PN30, MBP in the midbrain +
brainstem was 5 times that in the forebrain or
cerebellum. Further division of the brain into
subregions on PN30 revealed even larger dis-
tributional differences: values were highest in
the brainstem, followed by the midbrain and
striatum, whereas low values were seen in the
cerebral cortex and hippocampus. In keeping
with the fact that neurogenesis precedes
myelination (Rodier 1988), NF68 showed an
earlier ontogenetic increase than MBP (Figure
1B), with signiﬁcant regional differences pre-
sent as early as GD21. Again, by PN30, there
were large disparities between the midbrain +
brainstem and the forebrain or cerebellum;
with regional subdivision, the rank order was
brainstem > midbrain > striatum > cerebral
cortex > hippocampus. On PN30, NF200
(Figure 1C) showed a similar hierarchy. These
patterns for ontogeny and regional specializa-
tion of the neurofilament proteins are in
agreement with earlier results (Capano et al.
2001; Schlaepfer and Bruce 1990). None of
the regions showed signiﬁcant overall sex dif-
ferences or interactions of sex × other vari-
ables, so control values were combined across
males and females. However, as shown below,
sex differences did emerge in the effects of
CPF on these neuroproteins.
Global statistical analyses of chlorpyrifos
effects. We evaluated several data groupings
for main treatment effects and interactions
prior to subdividing data into separate treat-
ment regimens, sexes, and brain regions. We
first compared effects across all three regi-
mens (GD17–20, PN1–4, and PN11–14),
limiting the determinations to two brain
regions (midbrain + brainstem and forebrain),
one time point (24 hr posttreatment), and
without regard to sex, as all three regimens
shared only these variables. The result (CPF ×
regimen, p < 0.1) indicated the need to exam-
ine each regimen separately. Next, on PN30,
we compared the effects of CPF on the stria-
tum, a region for which all three regimens
and all three neuroproteins (MBP, NF68,
and NF200) were evaluated, this time includ-
ing sex as a factor. The outcome indicated the
need to subdivide the data by regimen and
sex (CPF × regimen × sex, p < 0.01). The
next grouping evaluated effects on PN30
across all six subregions (midbrain, brainstem,
cerebral cortex, hippocampus, striatum, and
cerebellum) for all three neuroproteins, deter-
minations that were shared only by the two
postnatal treatment regimens (PN1–4,
PN11–14), again including the sex variable.
This also indicated the need to look for treat-
ment-related differences after separating the
data by regimen and sex (CPF × sex,
p < 0.06; CPF × regimen × sex, p < 0.06).
Finally, because MBP and NF68 were evalu-
ated across three time points (24 hr after the
last injection, 5 days later, PN30) for both of
the postnatal treatment regimens, we con-
ducted analyses for those two regimens,
weighting the values for subregions on PN30
to obtain estimates for forebrain (cerebral cor-
tex + hippocampus + striatum) and midbrain
+ brainstem. For the PN11–14 treatment
group, we obtained interaction terms indica-
tive of treatment effects separable by sex and
by specific neuroprotein (CPF × sex, p <
0.04; CPF × sex × neuroprotein, p < 0.06).
Chlorpyrifos treatment on GD17–20.
CPF exposure from GD17–20 had a signiﬁ-
cant effect on MBP and NF68 on GD21, 24
hr after the last injection, characterized by a
significant increase (main effect of CPF),
assessed across both of the neuroproteins and
both regions (Figure 2A). Because there was
no interaction of treatment × other variables,
we did not conduct lower-order statistical
analyses for separate regions or neuroproteins,
but post hoc analysis across those factors indi-
cated significant increments at 5, 20 and 40
mg/kg/day of CPF. Multiple regression analy-
sis, including the factors of dose, neuroprotein
type, and brain region, conﬁrmed the signiﬁ-
cant relationship between dose and effect
(p < 0.0001). Earlier studies defined 10
mg/kg/day as the threshold for fetal weight
deﬁcits (Garcia et al. 2002; Qiao et al. 2002),
so it was evident that the immediate effects of
CPF on MBP and NF68 in the fetus involve
doses spanning that threshold. Accordingly,
we next assessed whether there might be
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Figure 1. Development of (A) MBP, (B) NF68, and (C) NF200 in control rat brain regions. Data represent means and standard errors obtained from 8 animals on
GD21 and from 8 to 16 animals for postnatal ages. ANOVA across regions, ages, and sex appears at the top of each panel  There were no signiﬁcant sex differ-
ences (no main effect of sex or interaction of sex × other variables), so the values are reported for the two sexes combined. For MBP (A) and NF68 (B), values at
the right represent subdivision of the midbrain + brainstem and forebrain into their component subregions. NF200 (C) was evaluated only on PN30. 
*Values after division of the midbrain + brainstem and forebrain into their subregions.
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istration, concentrating on the striatum, a
region that we previously found to be particu-
larly susceptible to subsequent emergence of
CPF-induced damage (Garcia et al. 2002;
Slotkin et al. 2002). Studies were limited to
doses below the threshold for fetal growth
impairment (1 or 5 mg/kg/day). On PN30,
measurements across all three neuroproteins
(MBP, NF68, NF200) indicated sex-depen-
dent effects of CPF (Figure 2B). Females
exposed to 5 mg/kg/day during fetal develop-
ment showed a signiﬁcant decrease in striatal
neuroproteins on PN30. Although effects
were not significant for 1 mg/kg/day when
compared with control values, the lower-dose
group also could not be distinguished statisti-
cally from the high-dose group, so an effect at
the lower dose could not be ruled out. In con-
trast to females, gestational CPF administra-
tion failed to cause signiﬁcant deﬁcits in males
and in fact tended to elevate the values. Again,
these results were confirmed by multiple
regression analysis (factors of dose and neuro-
protein type), which indicated a significant
dose–effect relationship in females (p < 0.008)
but not in males.
Postnatal chlorpyrifos treatment. CPF
administration on PN1–4 did not evoke sta-
tistically significant changes in MBP or
NF68, assessed 24 hr after the last injection
(PN5) or 5 days later on PN10 (Figure 3A).
Although there was an increase in the average
MBP value in the cerebellum on PN5, the
results for this region were highly variable at
this age, a likely consequence of its small size
and especially rapid rate of growth. Similarly,
there were no changes in MBP, NF68, or
NF200 in any of the subregions evaluated on
PN30 (Figure 3B). The absence of statisti-
cally signiﬁcant effects for this treatment regi-
men was itself distinguishable from the
significant differences seen for gestational
CPF treatment: comparing the significant
values for GD21 with those for PN5 (24 hr
after the last injection for each regimen),
treatment × regimen, p < 0.02. In the stria-
tum on PN30, values for the sex-dependent
effect of gestational CPF were similarly dis-
tinguishable from the lack of effect of the
PN1-4 regimen in the same region, as shown
by a significant interaction of treatment ×
regimen × sex, p < 0.05.
In contrast to the relative insensitivity to
CPF in the early postnatal treatment group,
CPF administration later in the neonatal
period, PN11–14, had sex-dependent effects
apparent in the immediate posttreatment
period (treatment × sex × neuroprotein,
p < 0.06) as well as on PN30 (treatment × sex,
p < 0.02). Male rats showed signiﬁcant deﬁcits
in MBP across all brain regions 24 hr after the
last CPF dose (PN15) as well as 5 days later
on PN20 (Figure 4A). NF68 did not show
significant deficits and, if anything, was
slightly increased in the midbrain + brain-
stem. Examination of subregions on PN30
(Figure 4B) confirmed that the deficits in
MBP persisted, now accompanied by equiva-
lent deficiencies in NF68 and NF200 (i.e.,
significant treatment effect across all three
neuroproteins with no distinction among
them). In contrast to the effects in males,
female rats showed no statistically signiﬁcant
effects of CPF treatment on PN11–14.
Rather than decreasing, values for MBP
tended to increase (albeit nonsigniﬁcantly) in
the forebrain on PN15 and cerebellum on
PN20 (Figure 4C). Similarly, for females,
there were no consistent changes across the
three protein markers in brain subregions on
PN30 (Figure 4D).
The preferential effect for males seen for
CPF administration on PN11–14 was distinct
from the lack of significant effect seen with
the earlier postnatal regimen (PN1–4) or from
the preferential effect on females seen with the
gestational regimen: on PN30, comparing all
subregions for the two postnatal regimens,
treatment × sex × regimen, p < 0.06; on
PN30, comparing values in the striatum
across all three regimens (CPF treatment on
GD17–20, PN1–4, PN11–14), treatment ×
sex × regimen, p < 0.02.
Discussion
In an earlier study (Garcia et al. 2002) with
the astrocyte marker GFAP, we found that
postnatal CPF treatment evoked an initial
deﬁcit, which is consistent with the view that
CPF targets the replication and differentia-
tion of these particular glial cells (Barone et
al. 2000; Garcia et al. 2001, 2002; Monnet-
Tschudi et al. 2000; Qiao et al. 2001).
However, later in development, GFAP was
elevated (Garcia et al. 2002), likely indicating
a subsequent phase of reactive gliosis (Norton
et al. 1992; O’Callaghan 1993), and thus
implying that other types of neural cells were
also affected adversely. In the current study,
we found that either prenatal or postnatal
CPF exposure evoked abnormalities in the
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Figure 2. Effects of gestational CPF exposure (GD17–20), assessed on GD21, 24 hr after the last CPF injec-
tion (A), or in the striatum on PN30 (B). Data represent means and standard errors obtained from four ani-
mals for each determination, presented as the percent change from control values (Figure 1). For GD21
(A), ANOVA across both brain regions and both neuroproteins appears at the top of the panel. Separate
analyses were not conducted for each region or neuroprotein because of the absence of a treatment ×
region or a treatment × neuroprotein interaction. For PN30 (B), ANOVA (shown above the panel) across all
neuroproteins and both sexes indicated a separation of CPF effects by sex. Separate ANOVAs for males
and females are shown within the panel.
*Doses whose values differ signiﬁcantly from the controls (assessed across both regions and both neuroproteins).
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brain subregions assessed on PN30. Data represent means and standard errors obtained from 8 to 16 ani-
mals for each determination, presented as the percent change from control values (Figure 1). ANOVA
across regions, ages and neuroproteins appears at the top of each panel. Values were combined for
males and females because of the absence of a treatment × sex interaction.
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ANOVA: NS ANOVA: NSexpression of neuroproteins associated with
oligodendrocytes (MBP), with neuronal cell
bodies (NF68), and with axonal projections
(NF200). Furthermore, exposure during dif-
ferent developmental periods exerted distinct
patterns; whereas prenatal or late postnatal
treatment had significant effects, CPF expo-
sure in the immediate neonatal period did
not. Superimposed on these effects were dif-
ferences in sex selectivity of effects for each
exposure period. The ﬁnding of two separable
developmental phases in which CPF affects
MBP, NF68, and NF200 thus confirms the
hypothesis that the developing brain repre-
sents a shifting target for CPF in which mul-
tiple processes are compromised over a wide
span of vulnerability.
When we administered CPF on PN11–14,
a peak period for gliogenesis, myelination, and
axonogenesis (Aschner et al. 1999; Barone et al.
2000; Compston et al. 1997; Riederer et al.
1992; Wiggins 1986), we found immediate
deficits in MBP and eventual deficits in all
three neuroproteins across all brain regions in
male rats. Combined with our earlier results
showing biphasic changes in GFAP with this
regimen (Garcia et al. 2002), the pattern is
entirely consistent with the view that, during
this stage, CPF interferes with development of
multiple types of cells, followed by reactive
astrogliosis. Although the PN11–14 treat-
ment window is outside the span of neuroge-
nesis in most of the regions affected (notably
excepting the cerebellum), the critical
involvement of glia in neuronal integrity,
axonogenesis, and synaptogenesis could
account for abnormalities including neuronal
markers such as NF68 and NF200. However,
it is equally likely that CPF interferes directly
with neurite extension and axonogenesis (Li
and Casida 1998; Sachana et al. 2001). At
this time, we have no definitive explanation
for the sex selectivity of the effects on neu-
rospeciﬁc proteins, but it is noteworthy that
the subsequent behavioral deficits are also
preferentially expressed in males (Levin et al.
2001), a completely different pattern from
that seen with CPF administration in adults.
Typically, CPF affects adult females more
than males (Gordon and Padnos 2000; Moser
2000), most likely because of differences in
CPF catabolism (Ma and Chambers 1994).
One possible mechanism for sex selectivity is
the differential levels of sex steroids within
the brain itself. Glial cells synthesize steroids
(Jung-Testas and Baulieu 1998), and the lev-
els of GFAP and MBP (and possibly other
neurospecific proteins) are hormonally
regulated (Jung-Testas and Baulieu 1998;
Melcangi et al. 1998). Further research may
need to focus on the impact of CPF exposure
on sex hormone synthesis and levels in the
developing brain and their participation in
neural development.
The late gestational period (GD17–20)
represented an entirely separate period of vul-
nerability to CPF, as characterized by imme-
diate and delayed effects on neurospecific
proteins. In this case, we saw an initial pro-
motional effect on GD21, indicating that the
consequences were completely different from
those seen with the PN11–14 exposure para-
digm. In our earlier study with GFAP, we
also saw enhancement after gestational CPF
exposure but only when the dose was raised
above the threshold for fetotoxicity (Garcia et
al. 2002). In the current experiments, MBP
and NF68 appeared to be slightly more sensi-
tive biomarkers of the effects of CPF. Later in
development (PN30), GFAP remained
within normal limits, whereas we found sig-
niﬁcant deﬁciencies for measurements across
the other markers. Additionally, with gesta-
tional CPF treatment, the sex preference was
distinct from that of the later CPF regimen,
as females were affected more than males. We
are thus faced with a number of interpreta-
tional questions. First, why is there an initial
increase in neurospeciﬁc proteins? The imme-
diate effects of CPF are likely to comprise
direct effects of CPF on neural cell develop-
ment as well as indirect effects mediated by
cholinesterase inhibition (Barone et al. 2000;
Mileson et al. 1998; Pope 1999; Slotkin
1999). With the gestational regimens used
here, there is signiﬁcant cholinesterase inhibi-
tion, and thus presumptively an increase in
cholinergic effects (Qiao et al. 2002). In turn,
enhanced cholinergic activity in the fetus can
augment synaptic plasticity and development
(Meck and Williams 1997, 1999; Montoya et
al. 2000), albeit at an eventual cost if cells are
forced into differentiation prematurely
(Navarro et al. 1989). We recently found that
in the fetus low doses of CPF can enhance
some biomarkers of cholinergic cell differenti-
ation (Qiao et al. 2002), so it is likely that the
effects on MBP and NF68 reflect a similar
mechanism.
The second issue raised by the effects of
gestational CPF exposure is why MBP, NF68,
and NF200 were affected more than GFAP
(Garcia et al. 2002). Here, it is important to
note that delineation of the levels of any of the
neurospecific proteins does not necessarily
reflect just the number of each cell type, as
specific protein expression is also subject to
regulation (Capano et al. 2001; Compston et
al. 1997). The changes seen here thus repre-
sent the net summation of damage to each
type of cell, disruption of the timetable for
differentiation, changes in the concentrations
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Figure 4. Effects of late neonatal CPF exposure (PN11–14) on neurospeciﬁc proteins. (A,C) Effects on MBP
and NF68, assessed on PN15 (24 hr after the last CPF injection) and PN20. (B,D) MBP, NF68, and NF200 in
brain subregions assessed on PN30. Data represent means and standard errors obtained from four to
eight animals for each determination, presented as the percent change from control values (Figure 1).
Values for males and females were separated because treatment effects were sex dependent: for PN15
and PN20 (A,C), treatment × sex × neuroprotein, p < 0.06; for PN30 (B,D), treatment × sex, p < 0.02. ANOVA
across regions, ages, and neuroprotein measure appears at the top of each panel with subdivision by neu-
roprotein where appropriate (A). Individual ages or treatments for which the CPF group differs from con-
trols were not assessed because of the absence of treatment × age or treatment × region interactions.
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Cerebellumof each protein within its own cell type, and
in the case of GFAP, the potential for reactive
changes when other cells are damaged
(Norton et al. 1992; O’Callaghan 1993).
Axonogenesis and myelination are interrelated
(Capano et al. 2001; Compston et al. 1997;
Lee and Cleveland 1996), so it is likely that
changes in glial markers (GFAP, MBP) inter-
act with those for development of the neu-
ronal neuroﬁlament proteins. Accordingly, the
greater apparent sensitivity of MBP, NF68,
and NF200, compared with that of GFAP,
needs to be interpreted with caution.
The sex-selective effects of gestational
CPF exposure raise a third question: Are the
preferential effects on females important for
the eventual outcome of CPF exposure? As
already discussed, a specific mechanism for
sex selectivity of fetal or neonatal effects of
CPF awaits elucidation. Nevertheless, it is
clear that the greater effects in females seen
here for neurospecific proteins have an
impact on subsequent behavioral perfor-
mance. We recently found that the gesta-
tional exposure paradigm, unlike postnatal
treatment, selectively affects cognitive perfor-
mance in females (Levin et al. 2002). Again,
regardless of mechanism, our results conﬁrm
the concept that the brain represents a shift-
ing target for CPF, with sex-selective effects
that differ substantially depending upon the
exposure window.
When CPF was administered in the early
neonatal period, PN1–4, there were no sig-
niﬁcant alterations in the three neuroproteins,
a puzzling finding in light of the clear-cut
synaptic and behavioral abnormalities that
result from this treatment regimen (Dam et
al. 1999, 2000; Levin et al. 2001; Slotkin
1999; Slotkin et al. 2001, 2002). Indeed, in
our earlier work with GFAP, we also found a
limited spectrum of changes with this expo-
sure (Garcia et al. 2002). Because the early
time points involved relatively large, hetero-
geneous brain regions, the lack of signiﬁcant
effects may be misleading, as changes in dis-
crete regions may be diluted by unaffected
areas (Garcia et al. 2002). However, the same
criticism could be mounted against the stud-
ies carried out in gestation or for the initial
time points with the PN11–14 regimen, and
we had no difﬁculty ﬁnding signiﬁcant differ-
ences with those regimens. Certainly one pos-
sibility is that the vulnerability of the
developing brain during this particular period
involves other developmental processes and
thus other neurospecific markers. Second,
because CPF is initially promotional for MBP
and NF68 with the gestational regimen and
inhibitory for the PN11–14 regimen, the
PN1–4 group may be in a range in which a
mixture of effects is occurring, with some cell
populations showing enhancement and oth-
ers showing deficits. A third possibility is a
technical issue: the immunoblotting tech-
nique may underestimate changes in treated
tissues because of the inﬂuence of competing
proteins that also change with development
(O’Callaghan et al. 1999). Obviously, exami-
nation of the underlying morphologic distrib-
ution of essential neuroproteins in the affected
brain regions, akin to preliminary results that
have appeared for gestational exposure
(Lassiter et al. 2002; White et al. 2002), will
be needed to resolve these possibilities.
A similar set of circumstances probably
limits the magnitude of CPF-induced changes
in neuroproteins even for the regimens pro-
ducing statistically significant differences. In
general, we found alterations of between 10
and 30%. However, none of the probes dis-
tinguishes whether these represent changes in
the numbers of oligodendrocytes (for MBP)
or axons (for the neuroﬁlament proteins), or
whether protein expression changes per cell or
axon. Accordingly, larger inherent alterations
in cell or axon number may be partially offset
by compensatory upregulation of the corre-
sponding neuroprotein in unaffected cells.
Furthermore, as shown by the control data for
PN30, the individual subregions contained
within the forebrain or midbrain + brainstem
have widely disparate levels of neuroproteins.
Thus, even a robust change in a small region,
such as the hippocampus or striatum, would
not be detected as a change in forebrain values,
as the bulk of the tissue is cerebral cortex.
Obviously, the answer to these questions lies in
morphologic examinations using immunocy-
tochemical techniques that localize the neuro-
proteins to anatomically discrete brain nuclei.
The results of this study reinforce the
view that the critical window of vulnerability
of the developing brain to CPF extends from
gestational exposure through later periods of
development in which glial-neuronal interac-
tions influence brain architecture, circuitry,
and function. Thus, exposures occurring
during childhood are likely to be as impor-
tant as those occurring prenatally. The corre-
lations between our neurochemical findings
for a shift in sex selectivity between fetal and
neonatal exposures, and the resultant behav-
ioral outcomes, point out the need to con-
sider sex as an important variable delineating
the developmental neurotoxicity of CPF.
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